磷酸肌酸钠治疗小儿原发性心肌炎的安全性评估

Safety Evaluation of Creatine Phosphate in Children with Primary Myocarditis

目的评估小儿原发性心肌炎使用磷酸肌酸钠治疗的安全性。方法纳入该次研究的对象是方便选取2016年3月—2017年3月该院收治的小儿原发性心肌炎96例患者,采用抽签法分为对照组和观察组,每组患者各48例,对照组采用常规方式治疗,观察组在常规治疗基础上使用磷酸肌酸钠治疗,比较两组患者的治疗效果和不良反应发生情况。结果观察组治疗后肌酸同工酶(CK-MB)(21.1±2.6)U/L、谷草转氨酶(AST)(32.2±4.6)U/L、乳酸脱氢酶-1(LDH-1)(55.2±7.4)U/L和心肌钙蛋白T(c Tn T)(1.2±0.1)U/L低于对照组,差异有统计学意义(t=15.09、9.376、10.17、10.95,P<0.05)。且观察组患儿临床疗效97.9%高于对照组85.4%,两组差异有统计学意义(χ2=4.909,P<0.05),且均未发生明显的不良反应。结论小儿原发性心肌炎患者使用磷酸肌酸钠治疗效果显著,安全性高,具有临床应用的价值。

Objective To evaluate the safety of using creatine phosphate in the treatment of primary myocarditis in children.Methods The subjects included in this study were 96 cases of primary myocarditis in children who were convenient admitted to the hospital from March 2016 to March 2017. They were divided into control group and observation group by lottery,48 cases in each group, and control group was treated with conventional method, the observation group was treated with sodium creatine phosphate on the basis of routine treatment. The treatment effects and adverse reactions of the two groups were compared. Results After treatment, creatine isoenzyme（CK-MB）（21.1±2.6） U/L, aspartate aminotransferase（AST）（32.2±4.6） U/L, lactate dehydrogenase-1（LDH-1） the difference were statistically significant（55.2±7.4） U/L and cardiac troponin T（c Tn T）（1.2 ± 0.1） U/L were lower than those in the control group（t=15.09, 9.376, 10.17, 10.95, P〈0.05）. The clinical efficacy of the observation group was 97.9% higher than that of the control group, which was 85.4%. There was a statistically significant difference between the two groups（χ2=4.909, P〈0.05）, and no significant adverse reactions occurred. Conclusion The use of sodium creatine phosphate in the treatment of children with primary myocarditis is effective, safe and has clinical application value.